home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

Succeed with the Tougher U.S. FDA cGMP Compliance Audits

 
  September 11, 2012  
     
 
ComplianceOnline, Online Event
2012-11-13


Why Should You Attend:

There is an on-going major shift in the emphasis of U.S. FDA CGMP compliance audits. These changes in focus have a major impact on individual compliance objectives, efforts and measurements of success.
The Agency has come under increasing negative publicity due to major, high profile drug and device problems / recalls, and public concerns over insufficient FDA oversight of new product introductions. In an effort to counter this public perception, FDA's audits have changed and have become less forgiving.

Businesses continue to "shoot itself in the foot", including once highly respected companies. All this affects the Agency's approach to audits and their expectations for companies. They also use GMP compliance audits to drive companies to do some of their work for them. And they're "piercing the corporate veil" to prosecute senior management involved in lying or fraud. There will be no return to the past.

During this session, we will evaluate the chief areas of an FDA CGMP compliance audit to see actual and anticipated changes in emphasis based on this new regulatory climate. Attending this training will enhance your awareness and provide you the understanding necessary to modify internal audits to match this FDA shift. Upon completion of this training, you will be in a position to evaluate your existing compliance and internal audit emphasis in light of the changes in the FDA's CGMP audit "paradigm", identify gaps and then put in place the necessary fixes to ensure continuing compliance.

Areas Covered in the Seminar:

  • The "target".
  • Avoid complacency from past "good" U.S. FDA/ EU ISO audits.
  • The desired response.
  • How to respond now -- where to shift focus first.
  • Where to direct scarce resources.
  • A risk-based phased approach.
  • Prove 'in control'.
  • Maintain 'the edge'.
Event Details:
 
Date:                    November 13, 2012
Time:                   10:00 AM-11:30 AM PDT
Cost:                    $299 per attendee per computer terminal
Registration:        SIgn-Up on-line now.  Add to your shopping cart.
 
 
Organized by: ComplianceOnline
Invited Speakers: John E. Lincoln, is Principal of J. E. Lincoln and Associates, a consulting company with over 29 years experience in U.S. FDA-regulated industries. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment including QMS and so+E6ftware validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files. He's held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D).
 
Deadline for Abstracts: 2012-11-13
 
Registration: http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=701432?channel=hummolgen
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.